========================================================
BRCA DRUG TARGET EXPLORATION v2
OrganismCore — Document 82
EZH2 convergence node — TNBC
========================================================

STEP 1: LOADING CACHE + METADATA
----------------------------------------
Loading cache: brca_saddle_results/expr_cache.csv
Cache shape: (100064, 16)
Loading metadata: Wu_etal_2021_BRCA_scRNASeq/metadata.csv
Metadata shape: (100064, 8)
Metadata columns: ['orig.ident', 'nCount_RNA', 'nFeature_RNA', 'percent.mito', 'subtype', 'celltype_subset', 'celltype_minor', 'celltype_major']

celltype_subset distribution (top 15):
celltype_subset
T_cells_c1_CD4+_IL7R            7786
Cancer LumA SC                  7742
Cancer Cycling                  5359
T_cells_c4_CD8+_ZFP36           5063
T_cells_c0_CD4+_CCR7            4952
Endothelial ACKR1               4611
Cancer Basal SC                 4312
T_cells_c2_CD4+_T-regs_FOXP3    4246
Cancer Her2 SC                  3708
Plasmablasts                    3524
PVL Differentiated s3           3487
Cancer LumB SC                  3368
T_cells_c7_CD8+_IFNG            3168
B cells Memory                  2581
CAFs MSC iCAF-like s1           2309
Name: count, dtype: int64

Common barcodes: 100064
Cache only:      0
Meta only:       0
  Cancer Basal SC               : n=4312
  Mature Luminal                : n=1265
  Luminal Progenitors           : n=1992
  Cancer LumA SC                : n=7742

========================================================
STEP 2: CONFIRMED ATTRACTOR
  Cancer Basal SC vs Mature Luminal
========================================================
TNBC (Cancer Basal SC): 4312
Mature Luminal:         1265
Genes in cache: ['FOXA1', 'GATA3', 'ESR1', 'SOX10', 'EZH2', 'MYC', 'MKI67', 'AR', 'ERBB2', 'KRT5', 'KRT8', 'SPI1', 'MBP', 'CDX2']

Gene expression: TNBC vs Luminal
Gene     | TNBC     | Luminal  | Change     | p-value
------------------------------------------------------------
FOXA1    | 0.0759   | 0.3934   | ↓80.7%     | p=8.34e-162 ***
GATA3    | 0.5181   | 1.1115   | ↓53.4%     | p=2.30e-104 ***
ESR1     | 0.0245   | 0.7489   | ↓96.7%     | p=0.00e+00 ***
SOX10    | 0.1170   | 0.0082   | ↑1323.3%     | p=8.83e-34 ***
EZH2     | 0.1530   | 0.0414   | ↑269.7%     | p=3.45e-27 ***
MYC      | 0.9998   | 1.1010   | ↓9.2%     | p=2.66e-06 ***
MKI67    | 0.0146   | 0.0016   | ↑787.9%     | p=7.87e-06 ***
AR       | 0.1453   | 0.9379   | ↓84.5%     | p=0.00e+00 ***
ERBB2    | 0.1464   | 0.5293   | ↓72.3%     | p=2.86e-152 ***
KRT5     | 0.4613   | 0.0759   | ↑507.9%     | p=2.48e-56 ***
KRT8     | 1.5243   | 2.2654   | ↓32.7%     | p=2.69e-98 ***
SPI1     | 0.0211   | 0.0088   | ↑141.1%     | p=1.85e-03 **
MBP      | 0.3009   | 0.1522   | ↑97.7%     | p=5.12e-19 ***
CDX2     | 0.0000   | 0.0000   | ↓0.0%     | p=1.00e+00 ns

========================================================
STEP 3: EZH2 CONVERGENCE NODE
========================================================
EZH2 FOUND IN CACHE

EZH2 in TNBC:    0.1530
EZH2 in Luminal: 0.0414
Change: +269.7%  p=3.45e-27
EZH2 ELEVATED IN TNBC ***
EZH2 IS the convergence node

EZH2 correlations in TNBC cells:
  EZH2 vs FOXA1 : r=+0.1306  p=7.42e-18 ***  [UNEXPECTED]
  EZH2 vs GATA3 : r=+0.2058  p=1.77e-42 ***  [UNEXPECTED]
  EZH2 vs ESR1  : r=+0.0300  p=4.87e-02 *  [UNEXPECTED]
  EZH2 vs SOX10 : r=+0.2576  p=2.69e-66 ***  [CORRELATED (expected)]

========================================================
STEP 4: ATTRACTOR DEPTH SCORING
========================================================
Within Cancer Basal SC cells:
Depth = switch genes suppressed
      + neural crest elevated
Deep cells = most locked in
false attractor = predicted
best responders to tazemetostat
Switch genes: ['FOXA1', 'GATA3', 'ESR1']
Neural crest: ['SOX10']
EZH2 in cache: True

Attractor depth statistics:
  Mean:   0.3474
  Median: 0.3333
  Std:    0.0805
  Min:    0.0000
  Max:    0.8773

Deep cells (top quartile):    n=1081
Shallow cells (bottom quartile):n=1288

Gene expression deep vs shallow:
Gene     | Deep     | Shallow  | Diff     | p
-------------------------------------------------------
FOXA1    | 0.1068   | 0.1575   | -0.0507  | p=2.27e-05 ***
GATA3    | 0.7519   | 1.0539   | -0.3020  | p=1.65e-24 ***
ESR1     | 0.0175   | 0.0640   | -0.0464  | p=1.52e-08 ***
SOX10    | 0.4583   | 0.0005   | +0.4578  | p=1.84e-179 ***
EZH2     | 0.5954   | 0.0011   | +0.5943  | p=1.52e-270 ***

Patient depth distribution:
  CID44971: depth=0.4061
  CID4523: depth=0.3590
  CID4495: depth=0.3589
  CID4465: depth=0.3372
  CID4515: depth=0.3346
  CID4066: depth=0.3333
  CID4067: depth=0.3333
  CID45171: depth=0.3333
  CID4513: depth=0.3284
  CID44991: depth=0.3275

========================================================
STEP 5: DRUG TARGET DERIVATION
========================================================
CONFIRMED SUPPRESSIONS:
  FOXA1 : 80.7% suppressed  p=8.34e-162
  GATA3 : 53.4% suppressed  p=2.30e-104
  ESR1  : 96.7% suppressed  p=0.00e+00

CONFIRMED ELEVATIONS (neural crest):
  SOX10 : ↑1323.3%  p=8.83e-34

ADDITIONAL FINDINGS:
  AR    : ↓84.5%  p=0.00e+00
  ERBB2 : ↓72.3%  p=2.86e-152
  KRT5  : ↑507.9%  p=2.48e-56
  KRT8  : ↓32.7%  p=2.69e-98
  MYC   : ↓9.2%  p=2.66e-06
  MKI67 : ↑787.9%  p=7.87e-06

========================================
ATTRACTOR TOPOLOGY:
========================================

The TNBC false attractor is
an EPIGENETICALLY LOCKED state.

NORMAL LUMINAL BREAST:
  FOXA1 (pioneer TF) opens
  chromatin at luminal enhancers
  → GATA3 binds → ESR1 activated
  → luminal differentiation complete
  EZH2 LOW — chromatin accessible

TNBC FALSE ATTRACTOR:
  EZH2 OVEREXPRESSED (PRC2 complex)
  → H3K27me3 deposited on:
    FOXA1 promoter/enhancer
    GATA3 locus
    ESR1 locus
  → Pioneer TF cannot bind
  → Luminal program LOCKED OUT
  → Neural crest program (SOX10)
    runs unopposed
  Self-reinforcing loop:
  EZH2↑ → FOXA1↓ → GATA3↓ →
  ESR1↓ → no luminal identity →
  EZH2 maintained

EZH2 IS THE CONVERGENCE NODE.
Same logic as GBM/OLIG2:
  GBM: EGFR/PDGFRA → OLIG2 lock
  TNBC: SOX10 program → EZH2 lock
Block the node → dissolve attractor

========================================
DRUG SEQUENCES:
========================================

SEQUENCE 1 — TWO-DRUG CONVERSION
  *** PRIMARY NOVEL PREDICTION ***

  Phase 1: Tazemetostat
    EZH2 inhibitor
    FDA approved: sarcoma, FL
    → EZH2 catalytic activity
      blocked
    → H3K27me3 marks gradually
      erased (replication-dependent)
    → FOXA1 binding sites open
    → FOXA1 re-expressed
    → GATA3 activated by FOXA1
    → ESR1 transcription begins
    → SOX10 neural crest suppressed
    Duration: 4-8 weeks
    Monitor: ctDNA ESR1
             methylation array

  Phase 2: Fulvestrant
    ESR1 degrader (SERD)
    FDA approved: ER+ breast
    → targets re-expressed ESR1
    → kills luminal-converted cells
    → attractor fully dissolved

  Clinical status:
    Tazemetostat: available
    Fulvestrant: available
    THIS SEQUENCE: NOT TESTED
    No clinical trial found

SEQUENCE 2 — THREE-DRUG
  Ludwig Cancer Research Oct 2024:
  EZH2i + AKTi in TNBC preclinical
  → tumor regression confirmed

  Phase 1: Tazemetostat
    → luminal conversion (as above)
  Phase 2: Capivasertib (AKTi)
    FDA approved: ER+ breast + AKTi
    → converted luminal cells
      activate AKT signaling
      (mammary involution pathway)
    → AKT inhibition kills
      luminal-converted cells
  Phase 3: Fulvestrant
    → ESR1+ survivor cleanup

  Clinical status:
    Capivasertib+fulvestrant:
    FDA approved for ER+ TNBC
    (CAPItello-291 trial)
    Tazemetostat BEFORE this:
    NOT TESTED
    The sequence is novel

SEQUENCE 3 — BIOMARKER-GUIDED
  Pre-treatment single-cell biopsy
  Measure:
    EZH2 expression
    SOX10 expression
    FOXA1/GATA3/ESR1 suppression
    = attractor depth score

  High depth score:
    → tazemetostat first
    → re-biopsy at 4 weeks
    → confirm ESR1 re-expression
    → capivasertib + fulvestrant

  Low depth score:
    (partial luminal retention)
    → capivasertib + fulvestrant
      directly (already targetable)

  This is attractor-guided
  precision medicine for TNBC.
  Requires scRNA-seq biopsy.
  Framework provides the score.

========================================================
STEP 6: GENERATING FIGURE
========================================================
Figure saved: brca_saddle_results/brca_drug_target_figure.png

========================================================
BRCA DRUG TARGET EXPLORATION COMPLETE
Results: brca_saddle_results/
Outputs: drug_target_log.txt
         brca_drug_target_figure.png
========================================================
